Orphazyme A/S – NASDAQ:ORPH
Orphazyme A/S stock price today
Orphazyme A/S stock price monthly change
Orphazyme A/S stock price quarterly change
Orphazyme A/S stock price yearly change
Orphazyme A/S key metrics
Market Cap | N/A |
Enterprise value | N/A |
P/E | -0.22 |
EV/Sales | N/A |
EV/EBITDA | 0.51 |
Price/Sales | N/A |
Price/Book | 0.65 |
PEG ratio | N/A |
EPS | -24.25 |
Revenue | N/A |
EBITDA | -496.77M |
Income | -485.37M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOrphazyme A/S stock price history
Orphazyme A/S stock forecast
Orphazyme A/S financial statements
| Mar 2019 | 0 | -84.37M | |
|---|---|---|---|
| Jun 2019 | 0 | -84.37M | |
| Jun 2020 | 0 | -125.70M | |
| Dec 2020 | 0 | -190.91M |
| Dec 2019 | 180754000 | 127.78M | 70.7% |
|---|---|---|---|
| Jun 2020 | 676360000 | 170.22M | 25.17% |
| Dec 2020 | 822493000 | 201.96M | 24.56% |
| Jun 2021 | 428031000 | 261.27M | 61.04% |
| Mar 2019 | -81.70M | -821.25K | 4.75K |
|---|---|---|---|
| Jun 2019 | -81.70M | -821.25K | 4.75K |
| Jun 2020 | 0 | -585K | 346.47M |
| Dec 2020 | 0 | -597.5K | 233.23M |
Orphazyme A/S alternative data
| Aug 2023 | 180 |
|---|---|
| Sep 2023 | 180 |
| Oct 2023 | 180 |
| Nov 2023 | 180 |
| Dec 2023 | 180 |
| Jan 2024 | 180 |
| Feb 2024 | 180 |
| Mar 2024 | 180 |
| Apr 2024 | 180 |
| May 2024 | 180 |
| Jun 2024 | 180 |
| Jul 2024 | 180 |
Orphazyme A/S other data
| Quarter | Transcript |
|---|---|
| Q2 2021 31 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA (1969) Chief Financial Officer | $881,030 |
-
What's the price of Orphazyme A/S stock today?
One share of Orphazyme A/S stock can currently be purchased for approximately $0.87.
-
When is Orphazyme A/S's next earnings date?
Unfortunately, Orphazyme A/S's (ORPH) next earnings date is currently unknown.
-
Does Orphazyme A/S pay dividends?
No, Orphazyme A/S does not pay dividends.
-
What is Orphazyme A/S's stock symbol?
Orphazyme A/S is traded on the NASDAQ under the ticker symbol "ORPH".
-
What is Orphazyme A/S's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Orphazyme A/S?
Shares of Orphazyme A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Orphazyme A/S's key executives?
Orphazyme A/S's management team includes the following people:
- Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA Chief Financial Officer(age: 56, pay: $881,030)
-
How many employees does Orphazyme A/S have?
As Jul 2024, Orphazyme A/S employs 180 workers.
-
When Orphazyme A/S went public?
Orphazyme A/S is publicly traded company for more then 5 years since IPO on 4 Sep 2020.
-
What is Orphazyme A/S's official website?
The official website for Orphazyme A/S is orphazyme.com.
-
How can i contact Orphazyme A/S?
Orphazyme A/S can be reached via phone at +45 39 17 82 72.
Orphazyme A/S company profile:
Orphazyme A/S
orphazyme.comNASDAQ
180
Biotechnology
Healthcare
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Copenhagen, 2200
CIK: 0001764791
ISIN: US6873051022
CUSIP: 687305102
